# Preclinical evaluation of HIV-1 envelope immunogens in humanized mice

> **NIH NIH N43** · NEOVAXSYN, INC. · 2022 · $300,000

## Abstract

Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates: The development of novel HIV candidate vaccines generally requires preclinical testing in animal models before proceeding to Phase I clinical trials. Multiple efforts have focused on developing and evaluating innovative platforms and formulations of HIV envelope (Env) immunogens for the induction and generation of a durable and broadly neutralizing antibody (bNAb) response. The goal of this program is to utilize genetically engineered mouse models, such as human immunoglobulin KI or other transgenic mice expressing relevant human genes, to accelerate testing and development of HIV vaccine candidates.

## Key facts

- **NIH application ID:** 10667351
- **Project number:** 75N93022C00029-0-9999-1
- **Recipient organization:** NEOVAXSYN, INC.
- **Principal Investigator:** VIKRAM SRIVASTAVA
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $300,000
- **Award type:** —
- **Project period:** 2022-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10667351

## Citation

> US National Institutes of Health, RePORTER application 10667351, Preclinical evaluation of HIV-1 envelope immunogens in humanized mice (75N93022C00029-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10667351. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*